Microgenics keeps technology in management buy-out
This article was originally published in Clinica
Microgenics is buying itself out of Roche Boehringer Mannheim, taking with it the intellectual property rights to the technology it developed before the company was sold, first to Boehringer, and subsequently, in the Boehringer deal, to Roche.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.